2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 220-222
Transfusion medicine is rapidly evolving from the delivery of standardized blood products toward precision, data-driven therapies tailored to individual patients and clinical contexts. This session highlights cutting-edge advances spanning the continuum of transfusion care. Topics range from optimizing stem cell mobilization and red cell exchange in patients with sickle cell disease, to reducing alloimmunization through precision antigen matching, improving hemostatic management in cardiac surgery, uncovering the biological effects of platelet transfusions on the developing brain, and developing next-generation recombinant oxygen-carrying blood substitutes. Together, these presentations demonstrate how innovations in transfusion science are improving the safety, effectiveness, and sustainability of blood therapies while laying the foundation for future alternatives to donor-derived blood.
Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

159 Multifunctional recombinant oxygen carrying volume expander protein as a blood alternative

Alejandra Lorenzen, BS, Lusha Xiang, PhD2, Min Ding, PhD3, Joshua Fenderson, MD4, Michael Meledeo, PhD5, Hanzhong Li, PhD6, Gang Huang, MD7
1 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
2 United States Army for Surgical Research, Fort Sam Houston, Texas, United States
3 Abioremedi, San Antonio, United States
4 United States Army for Surgical Research, Fort Sam Houston, Texas, United States
5 United States Army for Surgical Research, Fort Sam Houston, Texas, United States
6 Abioremedi, San Antonio, United States
7 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States

Introduction:

Whole blood (WB) transfusion is routine in hemorrhage resuscitation, aiding anemic cancer patients, and in perioperative blood management. Despite approximately 13.6 million units being transfused annually in the United States, supply of WB becomes severely constrained in rural environments and mass casualty events, creating severe constrains in emergency care. While the positive outcomes of WB use in patients are irrefutable, inconsistencies of supply in blood banks, questionable safety of the blood donated, and concern of acute hemolytic transfusion reactions highlight the importance of a readily available non-donor derived, oxygen carriers for transfusion. Prior research of perfluorocarbon (PFC) and hemoglobin-based oxygen carrier (HBOC) have encountered adverse effects in clinical trials ranging from hypertension to organ failure and death. Many of these adverse effects appear to be rooted in the designs of PFC and HBOCs. Without a protective membrane of a red blood cell, cell-free HBOCs disassemble, extravasate, and autoxidize, causing vasoconstriction, oxidative stress, and short circulation times.

To address these challenges, we have developed a series of recombinant Oxygen Carrying Volume Expanders (OCVEs) by fusion of monomeric globin with albumin. Our second generation, OCVE 2.0, links the monomeric globins myoglobin and neuroglobin to albumin, pairing tissue-specific globin oxygen-binding affinities with the volume-expanding and NO scavenging properties of albumin. We hypothesized that OCVE 2.0 would load and offload oxygen effectively and improve tissue oxygenation and survival in a rat hemorrhage model.

Methods:

OCVE 2.0 construct was expressed in CHO cells under serum-free conditions, purified via the Strep-II tag system, and confirmed by Western blot. Oxygen binding was assessed by oxygen dissociation assay with human fresh whole blood (fWB) as control. Samples were diluted to 10 µM in HEPES at pH 7.4 or 6.75, plated in a clear 96-well plate, and oxygenated at ambient air and temperature for 30 min; sodium dithionite (3 mM) served as a fully reduced reference. In a closed-system plate reader, N2 was blown over the plate (13 SCFH) for 60 min, with spectral scans (380–690 nm) at 0, 20, 60, and 80 min. P50 was measured on a Hemox TCS Analyzer against fWB and lyophilized hemoglobin (lyo Hb). Fractional saturation was derived per well by least-squares spectral deconvolution (500–620 nm) against oxygenated and dithionite-reduced basis spectra, then analyzed by mixed-model ANOVA with Holm-adjusted post hoc tests. In vivo, anesthetized rats underwent trauma and 45 min of pressure-controlled hemorrhagic shock (MAP ~55 mmHg), then received a single intravenous injection of saline, 25% human serum albumin, or OCVE 2.0 (n=5–7/group); MAP, tissue perfusion, tissue PO2, lactate, and survival were monitored for 2 hrs.

Results:

Under progressive N2 displacement, fWB desaturated more at pH 6.75 than at pH 7.4 (84.3±0.6% vs 96.1±1.2% at T80; interaction F(3,12)=22.03, p=0.006; divergence confined to T80, p=0.0024). OCVE 2.0 changed minimally at either pH, with Soret λmax fixed at 413–414 nm, though deoxygenated OCVE 2.0 showed a pH-dependent Q-band shift (A560/A530 1.52 vs 1.27). Dithionite resulted in deoxyhemoglobin of fWB (Soret 432 nm, Q 551 nm) but a bis-histidyl hexacoordinate spectrum in OCVE 2.0 (Soret 423 nm, Q 530 nm). P50 was 9.56 mmHg for OCVE 2.0 versus 17.59 for fWB and 5.25 for Lyo WB. In vivo, albumin and OCVE 2.0 both restored MAP and transiently improved perfusion. OCVE 2.0 had a sustained rise in tissue PO2, peaking above 50% of baseline. Survival was 100% with OCVE 2.0 versus 71% with albumin (p<0.01), and OCVE 2.0 reduced lactate (p=0.02 vs saline).

Conclusion:

We demonstrated OCVE 2.0 binds and releases oxygen with a P50 intermediate between fWB and Lyo WB, showing reversible oxygen carriage from a recombinant, non-donor-derived construct. Its higher affinity relative to fWB indicates that unloading requires lower tissue pO2 than native hemoglobin. Critically, OCVE 2.0 preserved tissue oxygenation, improved lactate balance, and conferred a survival advantage over albumin in severe hemorrhagic shock. This design represents a promising advance toward antigen- and pathogen-free blood substitutes for emergency medicine, rural healthcare, and mass casualty scenarios where WB is unavailable.

Alejandra Lorenzen, BS: No relevant conflicts of interest to declare.